LRMR
Larimar Therapeutics, Inc.- Healthcare
- Biotechnology
- $244M market cap
Forecast run · Oct 29, 2026Upside rank 624 of 3,186
Model Signal
ForecastQ Daily Probabilities
42.0%
66.9%
36.0%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$2.35
Price target$8.00
Implied move+240.4%
Analysts8
ForecastQ Portfolios
LRMR is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.